The variant NM_000551.3(VHL):c.461C>G (p.Pro154Arg) is a missense variant predicted to cause substitution of Proline by Arginine. This variant is in the nuclear export domain, a critical functional domain of VHL (PM1). The computational predictor REVEL gives a score of 0.942, which is above the threshold of >0.664, evidence that correlates with impact to VHL function (PP3). One subject age 40-45 is reported with paraganglioma (0.5 points). Of three commercial laboratories, two report no subjects with this variant. One laboratory reports two women in 60s and 70s with breast cancer (non-VHL related cancers), both having had multi-cancer and common cancer panels run. There is no further detail on phenotype/screening for VHL related phenotypes. Therefore the PS4 code is not met. The GroupMax Filtering Allele Frequency (95% CI) in gnomAD v4.1.0 is 0.00001425 (4/86248 from South Asian Population). This is lower than the ClinGen VHL VCEP threshold expected for VHL disease, of >=0.0000156 (0.00156%) for BS1, and therefore does not meet any criterion (BS1, BA1, PM2_Supporting are not met). Three other variants are reported in ClinVar at this position: Pro154Ala, Pro154Ser and Pro154Leu. All have Chuvash polycythemia and VHL as listed conditions. However, only Pro154Leu is reported as Pathogenic. Proline to Leucine is a distance of 98 and Proline to Arginine is a distance of 103 based on Grantham's table (1974). The Arginine substitution has a larger Grantham distance than Leucine. At this time the VHL VCEP has not classified Pro154Leu, and PM5 is not met. In summary, this variant meets the criteria to be classified as Uncertain for autosomal-dominant von Hippel Lindau syndrome (VHL syndrome) based on the ACMG/AMP criteria applied, as specified by the ClinGen VHL VCEP Version 1.0 (Specifications approval date: 02/26/2024. Variant Approval Date 06/25/2024).